Acutaas Chemicals delivered a landmark FY26: revenue ₹1,339 crore (+33% YoY), EBITDA ₹480 crore (~35% margin), PAT ₹356 crore, net cash ₹198 crore. Q4 EBITDA margin expanded 1,487 bps YoY — exceptional performance. CDMO target ₹1,000 crore by FY28; Indichem JV ₹190 crore. FY27: 25% revenue growth, ~35% EBITDA margin maintained. Good sentiment, high confidence (record financials, CDMO scaling, net cash, battery/semiconductor optionality).
Headline Numbers
| Metric | FY26 / Q4 FY26 | Notes |
|---|---|---|
| FY26 Revenue | ₹1,339 crore | +33% YoY; record |
| FY26 EBITDA | ₹480 crore | ~35% margin |
| FY26 PAT | ₹356 crore | — |
| Net Cash | ₹198 crore | — |
| FY26 Capex | ₹195 crore | — |
| Indichem JV Investment | ₹190 crore | Battery/semiconductor |
| Q4 EBITDA Margin Expansion | +1,487 bps YoY | — |
| Q4 PAT Margin Expansion | +1,070 bps YoY | — |
| FY27 Revenue Growth Guidance | 25% | — |
| FY27 EBITDA Margin | ~35% | Maintained |
| CDMO Revenue Target FY28 | ₹1,000 crore | — |
What Drove the Results
- Revenue +33%, EBITDA margin ~35% — specialty premium at scale: Acutaas growing 33% YoY while maintaining 35% EBITDA margins demonstrates specialty chemical pricing power. Commodity chemical companies grow revenue at 5-10% with 15-20% EBITDA margins. Acutaas's premium reflects its CDMO segment (customer-specific synthesis, high switching costs) and niche specialty products with limited domestic alternatives. At ₹1,339 crore scale with 35% EBITDA, Acutaas generates ₹480 crore EBITDA — substantial cash engine.
- Q4 EBITDA margin expansion 1,487 bps — mix shift + recovery: The 1,487 bps Q4 margin expansion is exceptional — reflecting semiconductor chemical demand recovery (global chip sector recovered through 2025-26 after inventory correction), CDMO ramp-up (higher-margin customer-specific projects), and operating leverage. This magnitude of margin expansion in a single quarter indicates both cyclical recovery and structural mix improvement.
- CDMO ₹1,000 crore FY28 target — transformational revenue stream: CDMO is Acutaas's highest-margin, most defensible business. Global pharma companies (US, Europe, Japan) outsource chemical synthesis to Indian CDMO providers for cost efficiency and regulatory compliance. At ₹1,000 crore CDMO revenue (at ~45% EBITDA), this segment alone would generate ₹450 crore EBITDA — nearly equal to today's entire company EBITDA. The CDMO build is Acutaas's valuation re-rating catalyst.
- Indichem JV ₹190 crore — battery + semiconductor positioning: Battery chemicals (electrolyte solvents, lithium salts) and semiconductor-grade chemicals (ultra-high purity solvents, etchants) are early-stage but structural growth markets. India's PLI for EV batteries and semiconductor fab incentives create captive domestic demand. Acutaas's early positioning via Indichem JV creates first-mover advantage in these niche supply chains.
- Net cash ₹198 crore — clean balance sheet funds growth: Generating ₹198 crore net cash while investing ₹195 crore capex and ₹190 crore in Indichem JV demonstrates Acutaas's strong underlying cash generation. No significant debt burden means FY27-28 cash flows can fund organic expansion, additional CDMO capacity, and potentially M&A without dilution.
What Management Said
Management was highly confident on growth trajectory and CDMO opportunity. On FY26: "Record revenue, record PAT — our CDMO expansion is working. Specialty chemicals demand is strong." On CDMO: "₹1,000 crore CDMO by FY28 — we have the pipeline, the technical capability, and the customer relationships. Execution is the focus." On Indichem: "₹190 crore JV investment in battery and semiconductor chemicals — we are early in these markets. FY28-FY30 is when this pays off." On FY27: "25% revenue growth at ~35% EBITDA — we are confident. New CDMO contracts, semiconductor recovery, and specialty expansion drive this." On R&D: "New R&D centre investment — our differentiation comes from molecular synthesis capability. We are investing in IP."
Key Tailwinds and Risks
Tailwinds:
- CDMO structural growth — global pharma outsourcing to India accelerating; Acutaas building customer relationships
- Semiconductor recovery — chip demand recovering globally; specialty chemical supply tightening
- Battery chemical optionality — India EV battery PLI creates domestic captive demand
- Net cash ₹198 crore — expansion funded without dilution
- EBITDA margin discipline — 35% maintained through scale; each revenue rupee adds at high incremental margin
Risks:
- CDMO client concentration — top 3-5 CDMO clients = revenue concentration risk
- Indichem JV execution — ₹190 crore investment must deliver on schedule
- Battery chemicals timeline — EV adoption slower than expected; revenue push-out
- Competition from larger CDMOs — Divi's, Aarti, Neogen have more scale
- Regulatory risk — USFDA/REACH compliance for CDMO requires ongoing investment
StockMirror AI Signal Summary
| Signal | Reading |
|---|---|
| Overall Sentiment | Good |
| Management Confidence | High |
| Prepared Remarks | Good — record FY26, 1,487 bps Q4 margin expansion, CDMO FY28 target |
| Q&A Sentiment | Good — confident on growth drivers, transparent on JV investment rationale |
| Revenue Growth | Strong — FY26 +33%; FY27 25% guidance |
| Margin Direction | Record high — 35% EBITDA; 1,487 bps Q4 expansion; sustained guidance |
| Earnings Quality | Strong — net cash ₹198 cr; CDMO mix improving; semiconductor recovery |
Track Acutaas Chemicals' full AI earnings breakdown — CDMO trajectory, Indichem JV progress, and margin sustainability — at Acutaas's earnings page.
Key Takeaways
- FY26 revenue ₹1,339 crore (+33%); EBITDA ₹480 crore (~35%); PAT ₹356 crore; net cash ₹198 crore
- Q4 EBITDA margin expanded 1,487 bps YoY — specialty mix and semiconductor recovery
- CDMO target ₹1,000 crore by FY28 — highest-margin, most defensible segment
- Indichem JV ₹190 crore in battery/semiconductor chemicals — early positioning for structural growth
- FY27: 25% revenue growth, ~35% EBITDA margin maintained
Related: Navin Fluorine Q4 FY26 · Epigral Q4 FY26
Disclaimer: This article is for informational purposes only and does not constitute investment advice. StockMirror's AI analysis is based on publicly available earnings transcripts and BSE/NSE filings. Please consult a SEBI-registered financial advisor before making investment decisions.